Vir Biotechnology (VIR) AI Stock Analysis

• Market Cap: $808.69M
• Dividend Yield: N/A
• Average Volume (3M): 1.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: -73.79%
• EPS Growth: -5.24%
• Country: US
• Employees: 408
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 138,238,000
• 10 Day Avg. Volume: 1,477,331
• 30 Day Avg. Volume: 1,176,367
• PEG Ratio: 0.12
• Price to Book (P/B): 0.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.72
• Enterprise Value/Market Cap: 0.69
• Enterprise Value/Revenue: 2.27
• Enterprise Value/Gross Profit: 41.18
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: $16.86
• Price Target Upside: 188.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 56 Neutral
• Price Target: $5.50 ▼(-5.98%Downside)

Vir Biotechnology's overall stock score is primarily impacted by financial volatility with declining revenue and profitability. Despite a strong balance sheet, cash flow issues raise liquidity concerns. The earnings call offered positive strategic insights, supporting the score, but valuation challenges due to financial losses remain significant.

Positive Factors

Clinical Development

Vir has successfully initiated its Phase 3 ECLIPSE program in chronic hepatitis delta, marking a significant milestone as they aim to develop a potential new standard of care for this high unmet need indication.

Financial Stability

With approximately $1.02B in cash and runway into mid-2027, full ownership of its key assets, and catalysts across both CHD and oncology, Vir is entering a more focused and potentially more investable phase of its lifecycle.

Market Opportunity

The focus on the Hepatitis Delta Virus program indicates a strong potential market opportunity.

Negative Factors

Competitive Positioning

Pasritamig's safety profile could challenge VIR-5500's competitive positioning, with only 9% Grade 1 CRS at RP2D compared to VIR-5500's 25% low-grade CRS rate.

Partnership Challenges

The prospects for a larger HBV partnership could be more challenging due to the recent data results.

Program Performance

The updated 24-week off-treatment data from the Phase 2 program (MARCH) did not meet functional cure thresholds needed to support a Phase 3 investment in the absence of a global partner in chronic hepatitis B virus (CHB).

Vir Biotechnology Business Overview & Revenue Model

Company Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

How the Company Makes Money

Vir Biotechnology generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These partnerships often include licensing agreements, milestone payments, and royalty revenues based on the successful development and commercialization of its therapeutic candidates. The company also seeks government grants and contracts to support its research and development efforts. For instance, Vir has entered into significant collaborations with companies like GlaxoSmithKline (GSK) to develop and commercialize antibodies for infectious diseases, including COVID-19 therapies. Revenue is also expected to be generated through the eventual sales of its proprietary products once they receive regulatory approval and are commercialized.

Vir Biotechnology Financial Statement Overview

Summary

Vir Biotechnology faces financial volatility with declining revenue and profitability. Despite a strong balance sheet with low leverage, the company has cash flow challenges highlighting potential liquidity issues. Stabilizing revenue and improving operational efficiencies are necessary for better financial performance.

Income Statement

Vir Biotechnology experienced significant revenue fluctuations, with a sharp decline from 2022 to 2023 and further into TTM (Trailing-Twelve-Months). The gross profit margin has decreased substantially, and the company recorded negative EBIT and net profit margins in recent periods, reflecting financial instability. Despite past profitability, recent performance indicates challenges in maintaining revenue and controlling costs.

Balance Sheet

The company maintains a solid equity position with a strong equity ratio, indicating financial stability. The debt-to-equity ratio is low, suggesting prudent leverage use. However, declining assets and equity from 2022 to TTM show potential risks if revenue and profitability do not improve.

Cash Flow

Operating cash flow has deteriorated significantly, leading to negative free cash flow in recent periods. The negative free cash flow to net income ratio suggests challenges in generating cash from operations. Despite high cash reserves, the negative trends in cash flow metrics indicate potential liquidity issues if not addressed.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	74.20M	86.18M	1.58B	1.09B	67.25M
Gross Profit	73.36M	83.42M	1.43B	1.02B	-234.33M
EBITDA	-537.61M	-664.85M	833.07M	420.75M	-289.80M
Net Income	-521.96M	-615.06M	515.84M	528.58M	-298.67M
Balance Sheet
Total Assets	1.40B	1.92B	2.80B	1.95B	918.76M
Cash, Cash Equivalents and Short-Term Investments	990.38M	1.52B	2.40B	708.14M	736.86M
Total Debt	97.89M	124.54M	127.97M	133.56M	66.56M
Total Liabilities	248.43M	328.82M	724.13M	522.42M	201.91M
Stockholders Equity	1.15B	1.59B	2.08B	1.43B	716.85M
Cash Flow
Free Cash Flow	-453.65M	-800.36M	1.60B	-69.41M	-197.49M
Operating Cash Flow	-446.35M	-778.78M	1.66B	-47.59M	-190.94M
Investing Cash Flow	499.37M	164.63M	-1.19B	-140.81M	-9.86M
Financing Cash Flow	4.39M	7.48M	34.76M	100.33M	529.47M

Vir Biotechnology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.85
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIR, the sentiment is Positive. The current price of 5.85 is above the 20-day moving average (MA) of 5.48, above the 50-day MA of 5.19, and below the 200-day MA of 7.21, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 58.00 is Neutral, neither overbought nor oversold. The STOCH value of 66.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VIR.

Vir Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	61 Neutral	$1.40B	―	-57.92%	―	-13.37%	2.57%
VIR	56 Neutral	$808.69M	―	-44.59%	―	-73.79%	-5.24%
RCUS	55 Neutral	$1.03B	―	-63.17%	―	-40.51%	-35.07%
NRIX	53 Neutral	$889.11M	―	-50.67%	―	41.86%	10.48%
Sector *	52 Neutral	$7.62B	0.05	-63.03%	2.44%	16.33%	0.31%
SYRE	43 Neutral	$1.07B	2.31	-50.47%	―	-100.00%	94.68%
PHVS	42 Neutral	$1.14B	―	-51.85%	―	―	0.71%

Vir Biotechnology Corporate Events

Vir Biotechnology Holds 2025 Annual Stockholder Meeting

On May 29, 2025, Vir Biotechnology, Inc. held its 2025 Annual Meeting of Stockholders, where key decisions were made. Stockholders elected two Class III directors, approved executive compensation, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (VIR) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Vir Biotechnology stock, see the VIR Stock Forecast page.

Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data

On May 9, 2025, Vir Biotechnology announced 24-week post-treatment data from its MARCH Phase 2 study on tobevibart and elebsiran for chronic hepatitis B, presented at the EASL Congress in Amsterdam. The study showed HBsAg loss in 17% and 21% of participants with low baseline HBsAg levels, using the combination with or without pegylated interferon alpha. Despite the promising results, Vir has not secured a development partner for further Phase 3 trials and will streamline the final stages of the Phase 2 study, aligning with its focus on the ECLIPSE Phase 3 program for hepatitis delta and oncology initiatives. The company maintains its cash runway guidance into mid-2027.